← Back to Clinical Trials
Recruiting Phase 3 NCT04356326

NCT04356326 Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04356326
Status Recruiting
Phase Phase 3
Sponsor Centre Hospitalier Intercommunal Creteil
Condition Chronic Hypertension Complicating Pregnancy
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2021-02-15
Primary Completion 2026-02

Trial Parameters

Condition Chronic Hypertension Complicating Pregnancy
Sponsor Centre Hospitalier Intercommunal Creteil
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 500
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2021-02-15
Completion 2026-02
Interventions
Aspirin 150 mgPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg/day started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.

Eligibility Criteria

Inclusion Criteria: * Pregnant patient between 10 and 19 weeks of gestation + 6 days * Chronic hypertension, whether treated or not, know before pregnancy or diagnosed before randomization * Singleton pregnancy * Signed the written informed consent * Affiliation to social security Exclusion Criteria: * ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical heart valves), * Patient receiving aspirin for another indication outside pregnancy, * Patient with significant proteinuria (\> 300mg/24 hours or a proteinuria/creatininuria ratio ≥ 30mg/mmol), * Active bleeding, * History of severe PE with delivery \< 34 weeks of gestation, * Hypersensitivity to salicylates such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), * Platelet count lower than 100,000 cells/microliter (dosage less than 6 months old), * Hemostasis disorders, including hemophilia (with thrombo

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology